Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Pharmacovigilance and new essential drugs in Africa: Zambia draws lessons from its own experiences and beyond.

Huff-Rousselle M, Simooya O, Kabwe V, Hollander I, Handema R, Mwango A, Mwape E.

Glob Public Health. 2007;2(2):184-203. doi: 10.1080/17441690601063299.

PMID:
19280399
2.
3.

A situational analysis of pharmacovigilance plans in the Global Fund Malaria and U.S. President's Malaria Initiative proposals.

Stergachis A, Bartlein RJ, Dodoo A, Nwokike J, Kachur SP.

Malar J. 2010 May 30;9:148. doi: 10.1186/1475-2875-9-148.

4.

Pharmacovigilance of antimalarial treatment in Africa: is it possible?

Talisuna AO, Staedke SG, D'Alessandro U.

Malar J. 2006 Jun 16;5:50.

5.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
8.
9.

Conquering the intolerable burden of malaria: what's new, what's needed: a summary.

Breman JG, Alilio MS, Mills A.

Am J Trop Med Hyg. 2004 Aug;71(2 Suppl):1-15. Review.

PMID:
15331814
10.

[Pharmacovigilance as new direction of research].

Gaszner G, Makkos Z, Gaszner P.

Neuropsychopharmacol Hung. 2005 Dec;7(4):194-8. Hungarian.

PMID:
16496484
11.

Contribution of Latin America to pharmacovigilance.

González JC, Arango VE, Einarson TR.

Ann Pharmacother. 2006 Jul-Aug;40(7-8):1394-99. Review.

PMID:
16868216
12.

Pilot study of essential drug quality in two major cities in India.

Bate R, Tren R, Mooney L, Hess K, Mitra B, Debroy B, Attaran A.

PLoS One. 2009 Jun 23;4(6):e6003. doi: 10.1371/journal.pone.0006003.

13.

The monitoring medicines project: a multinational pharmacovigilance and public health project.

Pal SN, Olsson S, Brown EG.

Drug Saf. 2015 Apr;38(4):319-28. doi: 10.1007/s40264-015-0283-y.

14.

Specific features of medicines safety and pharmacovigilance in Africa.

Isah AO, Pal SN, Olsson S, Dodoo A, Bencheikh RS.

Ther Adv Drug Saf. 2012 Feb;3(1):25-34. doi: 10.1177/2042098611425695. Review.

15.

Forensic pharmacovigilance and substandard or counterfeit drugs.

Labadie J.

Int J Risk Saf Med. 2012;24(1):37-9. doi: 10.3233/JRS-2012-0551.

PMID:
22436258
16.

[Pharmacovigilance in practice].

Spreux A, Baldin B, Chichmanian RM.

Transfus Clin Biol. 1999 Jul;6(4):254-9. French.

PMID:
10472690
17.

Veterinary pharmacovigilance in the European context.

Keck G.

Ann Ist Super Sanita. 1992;28(4):425-8.

PMID:
1303032
18.

An Italian approach to postmarketing monitoring: preliminary results from the SCOLTA (Surveillance Cohort Long-Term Toxicity Antiretrovirals) project on the safety of lopinavir/ritonavir.

Bonfanti P, Martinelli C, Ricci E, Carradori S, Parruti G, Armignacco O, Magnani C, Quirino T; CISAI Group (Italian Coordinators for the Study of Allergies HIV Infection).

J Acquir Immune Defic Syndr. 2005 Jul 1;39(3):317-20.

PMID:
15980692
19.

Post Launch Monitoring of food products: what can be learned from pharmacovigilance.

van Puijenbroek EP, Hepburn PA, Herd TM, van Grootheest AC.

Regul Toxicol Pharmacol. 2007 Mar;47(2):213-20. Epub 2007 Jan 3.

PMID:
17204356
20.

Pharmacovigilance of antimalarial treatment in Uganda: community perceptions and suggestions for reporting adverse events.

Bukirwa H, Nayiga S, Lubanga R, Mwebaza N, Chandler C, Hopkins H, Talisuna AO, Staedke SG.

Trop Med Int Health. 2008 Sep;13(9):1143-52. doi: 10.1111/j.1365-3156.2008.02119.x. Epub 2008 Jul 8.

Supplemental Content

Support Center